Puma Biotechnology, Inc. (PBYI) announced that it has initiated the phase II ALISCA-Breast1 study evaluating its pipeline candidate, alisertib, for the treatment of patients with metastatic breast cancer.The ALISCA-Breast1 study is investigating alisertib in combination with endocrine therapy for treating hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-negative) recurrent or metastatic breast cancer in patients who have been previously treated with CDK 4/6 inhibitors ...